Synonyms: compound 195 [WO2021113557A1] | NX5948
Compound class:
Synthetic organic
Comment: NX-5948 (Nurix Therapeutics) is an oral BTK protein degrader. It was designed as an alternative to BTK inhibitors for potential to treat B cell malignancies, including those that carry BTK mutations which confer resistance to existing BTK inhibitors [1-2]. In contrast to NX-2127 which degrades both BTK and IKZF3, NX-5948 selectively degrades BTK. We believe NX-5948 is compound 195 in patent WO2021113557A1 [3].
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 Interventional | Nurix Therapeutics, Inc. |